AMG National Trust Bank Sells 12,718 Shares of GSK plc (NYSE:GSK)

AMG National Trust Bank trimmed its position in GSK plc (NYSE:GSK - Free Report) by 22.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 44,611 shares of the pharmaceutical company's stock after selling 12,718 shares during the period. AMG National Trust Bank's holdings in GSK were worth $1,501,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of GSK. Sunbelt Securities Inc. boosted its position in shares of GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock worth $29,000 after purchasing an additional 302 shares during the last quarter. Indiana Trust & Investment Management Co lifted its holdings in GSK by 200.0% during the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock worth $25,000 after acquiring an additional 500 shares in the last quarter. Crews Bank & Trust bought a new position in GSK during the fourth quarter worth about $26,000. ST Germain D J Co. Inc. lifted its holdings in GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock worth $27,000 after acquiring an additional 522 shares in the last quarter. Finally, Sierra Ocean LLC bought a new position in GSK during the fourth quarter worth about $32,000. 15.74% of the stock is currently owned by institutional investors.

GSK Stock Up 2.0 %

Shares of NYSE GSK traded up $0.78 during trading hours on Friday, hitting $40.08. The company had a trading volume of 8,122,019 shares, compared to its average volume of 5,002,241. The stock has a market capitalization of $83.07 billion, a P/E ratio of 25.21, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.92. The firm's 50 day moving average is $35.47 and its 200-day moving average is $37.17.

Remove Ads

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, analysts expect that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be issued a dividend of $0.3932 per share. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a dividend yield of 3.92%. This is an increase from GSK's previous quarterly dividend of $0.39. GSK's dividend payout ratio (DPR) is currently 98.74%.

Analysts Set New Price Targets

GSK has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft lowered GSK from a "buy" rating to a "hold" rating in a report on Friday, November 15th. Morgan Stanley initiated coverage on shares of GSK in a research note on Wednesday, February 12th. They set an "equal weight" rating for the company. StockNews.com raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 7th. Finally, Jefferies Financial Group cut shares of GSK from a "buy" rating to a "hold" rating and decreased their price target for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Seven research analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.